Gertrudis Rojas

Dr. Gertrudis Rojas


Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 December 2021 in RSC Chemical Biology
Verified
Journal Article
Open access
PDF file
DSDarielys Santana-Mederos
Darielys Santana-Mederos
RPRocmira Pérez-Nicado
Rocmira Pérez-Nicado
YCYanet Climent
Yanet Climent
LRLaura Rodriguez
Laura Rodriguez
BRBelinda Sanchez Ramirez
Belinda Sanchez Ramirez
VBVicente Verez Bencomo
Vicente Verez Bencomo
Soberana01 is composed of the SARS-CoV-2 dimeric RBD and Neisseria meningitidis outer membrane vesicles (OMVs) adsorbed on alum. This vaccine induces a potent neutralizing immune response and shows potential against SARS-CoV-2 variants of concern.

2 November 2014 in mAbs
Verified
Journal Article
Closed access
GRGertrudis Rojas
Gertrudis Rojas
YTYaima Tundidor
Yaima Tundidor
YIYanelys Cabrera Infante
Yanelys Cabrera Infante
Antibody engineering must be accompanied by mapping strategies focused on identifying the epitope recognized by each antibody to define its unique functional identity. High throughput fine specificity determination remains technically challenging. We review recent experiences aimed at revisiting the oldest and most extended display technology to develop a robust epitope mapping platform, based on the ability to manipulate target-derived molecules (ranging from the whole native antigen to antigen domains and smaller fragments) on filamentous phages. Single, multiple and combinatorial mutagenesis allowed comprehensive scanning of phage-displayed antigen surface that resulted in the identification of clusters of residues contributing to epitope formation. Functional pictures of the epitope(s) were thus delineated in the natural context. Successful mapping of antibodies against interleukin-2, epidermal growth factor and its receptor, and vascular endothelial growth factor showed the versatility of these procedures, which combine the accuracy of site-directed mutagenesis with the high throughput potential of phage display.

19 November 2013 in mAbs
Verified
Journal Article
Open access
PDF file
GRGertrudis Rojas
Gertrudis Rojas
YIYanelys Cabrera Infante
Yanelys Cabrera Infante
APAmaury Pupo
Amaury Pupo
TCTania Carmenate
Tania Carmenate
The functional dichotomy of antibodies against interleukin-2 (IL-2) is thought to depend upon recognition of different cytokine epitopes. Beyond functional studies, the only molecular evidence obtained so far located the epitopes recognized by the immunoenhancing antibodies S4B6 and JES6–5H4 within the predicted interface of IL-2 with the α receptor subunit, explaining the preferential stimulation of effector cells displaying only β and γ receptor chains. A consistent functional map of the epitope bound by the immunoregulatory antibody JES6-1A12 has now been delineated by screening the interactions of phage-displayed antigen variants (with single and multiple mutations) and antigen mimotopes. The target determinant resides in a region between the predicted interfaces with α and β/γ receptor subunits, supporting the dual inhibitory role of the antibody on both interactions. Binding by JES6-1A12 would thus convert complexed IL-2 into a very weak agonist, reinforcing the advantage of T regulatory cells (displaying the high affinity αβγ heterotrimeric receptor) to capture the cytokine by competition and expand over effector cells, ultimately resulting in the observed strong tolerogenic effect of this antibody. Detailed knowledge of the epitopes recognized by anti-IL-2 antibodies with either immunoenhancing or immunoregulatory properties completes the molecular scenario underlying their use to boost or inhibit immune responses in multiple experimental systems. The expanded functional mapping platform now available could be exploited to study other interactions involving related molecular pairs with the final goal of optimizing cytokine and anti-cytokine therapies.

1 January 2013 in Immunobiology
Verified
Journal Article
Closed access
GRGertrudis Rojas
Gertrudis Rojas
APAmaury Pupo
Amaury Pupo
KLKalet Leon
Kalet Leon
JAJanet Avellanet
Janet Avellanet
TCTania Carmenate
Tania Carmenate
SSSachdev Sidhu
Sachdev Sidhu

23 April 2014 in mAbs
Verified
Journal Article
Closed access
YTYaima Tundidor
Yaima Tundidor
CGClaudia Patricia García-Hernández
Claudia Patricia García-Hernández
APAmaury Pupo
Amaury Pupo
YIYanelys Cabrera Infante
Yanelys Cabrera Infante
GRGertrudis Rojas
Gertrudis Rojas
Molecular details of epidermal growth factor receptor (EGFR) targeting by nimotuzumab, a therapeutic anti-cancer antibody, have been largely unknown. The current study delineated a functional map of their interface, based on phage display and extensive mutagenesis of both the target antigen and the Fv antibody fragment. Five residues in EGFR domain III (R353, S356, F357, T358, and H359T) and the third hypervariable region of nimotuzumab heavy chain were shown to be major functional contributors to the interaction. Fine specificity differences between nimotuzumab and other anti-EGFR antibodies were revealed. Mapping information guided the generation of a plausible in silico binding model. Knowledge about the epitope/paratope interface opens new avenues for the study of tumor sensitivity/resistance to nimotuzumab and for further engineering of its binding site. The developed mapping platform, also validated with the well-known cetuximab epitope, allows a comprehensive exploration of antigenic regions and co...

3 March 2014 in mAbs
Verified
Journal Article
Closed access
YIYanelys Cabrera Infante
Yanelys Cabrera Infante
APAmaury Pupo
Amaury Pupo
GRGertrudis Rojas
Gertrudis Rojas
Although multiple different procedures to characterize the epitopes recognized by antibodies have been developed, site-directed mutagenesis remains the method of choice to define the energetic contribution of antigen residues to binding. These studies are useful to identify critical residues and to delineate functional maps of the epitopes. However, they tend to underestimate the roles of residues that are not critical for binding on their own, but contribute to the formation of the target epitope in an additive, or even cooperative, way. Mapping antigenic determinants with a diffuse energetic landscape, which establish multiple individually weak interactions with the antibody paratope, resulting in high affinity and specificity recognition of the epitope as a whole, is thus technically challenging. The current work was aimed at developing a combinatorial strategy to overcome the limitations of site-directed mutagenesis, relying on comprehensive randomization of discrete antigenic regions within phage-displayed antigen libraries. Two model antibodies recognizing epidermal growth factor were used to validate the mapping platform. Abrogation of antibody recognition due to the introduction of simultaneous replacements was able to show the involvement of particular amino acid clusters in epitope formation. The abundance of some of the original residues (or functionally equivalent amino acids sharing their physicochemical properties) among the set of mutated antigen variants selected on a given antibody highlighted their contributions and allowed delineation of a detailed functional map of the corresponding epitope. The use of the combinatorial approach could be expanded to map the interactions between other antigens/antibodies.